Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
Advertisement
Articles by Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
3
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
4
Will Cancer Care Come Home by 2030? PCOC Panelists Differ on Strategy
5